Compound Detail
CHEMBL522892
DOVITINIB 🧪 Phase III
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
🧪 Phase III
Basic Information
| ChEMBL ID | CHEMBL522892 |
| Name | DOVITINIB |
| Phase | Phase III |
| Structure Type | MOL |
| InChI Key | PIQCTGMSNWUMAF-UHFFFAOYSA-N |
227
Targets
560
Activities
4
Assay Types
10
PK Parameters
20
Publications
5
Known Names
20
Indications
5
Mechanisms
Molecular Properties
392.4
MW (Da)
2.54
ALogP
5
HBA
3
HBD
94.0
PSA (Ų)
0.49
QED
0
Ro5 Violations
2
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| Chirality | Achiral |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Fibroblast growth factor receptor 3 inhibitor | INHIBITOR | Fibroblast growth factor receptor 3 | ✓ | ✓ |
| Tyrosine-protein kinase receptor FLT3 inhibitor | INHIBITOR | Receptor-type tyrosine-protein kinase FLT3 | ✓ | ✓ |
| Stem cell growth factor receptor inhibitor | INHIBITOR | Mast/stem cell growth factor receptor Kit | ✓ | ✓ |
| Platelet-derived growth factor receptor inhibitor | INHIBITOR | Platelet-derived growth factor receptor | ✓ | ✓ |
| Vascular endothelial growth factor receptor inhibitor | INHIBITOR | Vascular endothelial growth factor receptor | ✓ | ✓ |
Indications
Carcinoma, Renal Cell Carcinoma, Renal Cell Adrenal Cortex Neoplasms Brain Neoplasms Breast Neoplasms Carcinoma, Adenoid Cystic Carcinoma, Hepatocellular Carcinoma, Non-Small-Cell Lung Endometrial Neoplasms Gastrointestinal Stromal Tumors Glioblastoma Glioblastoma Gliosarcoma Mesothelioma Multiple Myeloma Neoplasms Neoplasms Pheochromocytoma Prostatic Neoplasms, Castration-Resistant Stomach Neoplasms
Activity Summary
Kd 411 meas. best 9.52
Ki 83 meas. best 8.5
IC50 62 meas. best 9.0
EC50 4 meas. best 7.89
Target Activity Profile
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| AUC | 6000.0 | ng.hr.mL-1 | Mus musculus |
| AUC | 5666.67 | ng.hr.mL-1 | Rattus norvegicus |
| CL | 42.0 | mL.min-1.kg-1 | Mus musculus |
| CL | 43.0 | mL.min-1.kg-1 | Rattus norvegicus |
| Cmax | 1707.27 | nM | Mus musculus |
| Cmax | 1223.12 | nM | Rattus norvegicus |
| F | 77.0 | % | Mus musculus |
| F | 73.0 | % | Rattus norvegicus |
| T1/2 | 2.7 | hr | Mus musculus |
| T1/2 | 3.5 | hr | Rattus norvegicus |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 26254279 | 10.18632/oncotarget.4214 | Unchecked | 20 |
| 22037378 | 10.1038/nbt.1990 | Tyrosine-protein kinase ABL1 | 15 |
| 22037378 | 10.1038/nbt.1990 | Epidermal growth factor receptor | 12 |
| 22037378 | 10.1038/nbt.1990 | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | 10 |
| 18183025 | 10.1038/nbt1358 | Epidermal growth factor receptor | 10 |
| 22037378 | 10.1038/nbt.1990 | Mast/stem cell growth factor receptor Kit | 8 |
| 19113866 | 10.1021/jm800790t | Mus musculus | 8 |
| 22037378 | 10.1038/nbt.1990 | Receptor-type tyrosine-protein kinase FLT3 | 7 |
| 18183025 | 10.1038/nbt1358 | Tyrosine-protein kinase ABL1 | 7 |
| 19113866 | 10.1021/jm800790t | Rattus norvegicus | 6 |
| 19113866 | 10.1021/jm800790t | MV4-11 | 6 |
| 18183025 | 10.1038/nbt1358 | Receptor-type tyrosine-protein kinase FLT3 | 6 |
| 19113866 | 10.1021/jm800790t | NON-PROTEIN TARGET | 6 |
| 19113866 | 10.1021/jm800790t | DU-145 | 5 |
| 18183025 | 10.1038/nbt1358 | Mast/stem cell growth factor receptor Kit | 5 |
| 29191878 | 10.1126/science.aan4368 | Unchecked | 5 |
| - | 10.1039/C5MD00090D | TRAF2 and NCK-interacting protein kinase | 5 |
| 22037378 | 10.1038/nbt.1990 | Proto-oncogene tyrosine-protein kinase receptor Ret | 4 |
| - | 10.6019/CHEMBL4495565 | SARS-CoV-2 | 4 |
| - | 10.6019/CHEMBL4808148 | Histone deacetylase 6 | 3 |
Data from ChEMBL 36 via Core Engine